Healthcare provider profile · identity verified

Samuel C Ogden, M.D.

Family Practice · COLORADO SPRINGS, CO · NPI 1710945738

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	463	34
Eliquis	Apixaban	408	27
Atorvastatin Calcium	Atorvastatin Calcium	326	42
Amlodipine Besylate	Amlodipine Besylate	192	26
Sertraline Hcl	Sertraline Hcl	182	24
Gabapentin	Gabapentin	166	27
Tamsulosin Hcl	Tamsulosin Hcl	153	21
Lisinopril	Lisinopril	142	22
Carvedilol	Carvedilol	139	19
Rosuvastatin Calcium	Rosuvastatin Calcium	135	15
Pantoprazole Sodium	Pantoprazole Sodium	129	22
Furosemide	Furosemide	107	16
Potassium Chloride	Potassium Chloride	106	17
Citalopram Hbr	Citalopram Hydrobromide	101	12
Trazodone Hcl	Trazodone Hcl	87	16
Oxycodone Hcl	Oxycodone Hcl	81	21
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	80	suppressed
Metformin Hcl	Metformin Hcl	78	suppressed
Metoprolol Succinate	Metoprolol Succinate	77	12
Quetiapine Fumarate	Quetiapine Fumarate	77	12
Escitalopram Oxalate	Escitalopram Oxalate	71	suppressed
Lorazepam	Lorazepam	70	18
Baclofen	Baclofen	65	suppressed
Mirtazapine	Mirtazapine	64	13
Pregabalin	Pregabalin	60	suppressed
Dapagliflozin	Dapagliflozin Propanediol	59	suppressed
Lactulose	Lactulose	59	suppressed
Risperidone	Risperidone	59	13
Famotidine	Famotidine	56	15
Alendronate Sodium	Alendronate Sodium	55	12
Losartan Potassium	Losartan Potassium	54	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	52	suppressed
Finasteride	Finasteride	50	suppressed
Rexulti	Brexpiprazole	50	suppressed
Clopidogrel	Clopidogrel Bisulfate	48	suppressed
Bydureon Bcise	Exenatide Microspheres	47	suppressed
Latanoprost	Latanoprost	46	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	43	suppressed
Bupropion Xl	Bupropion Hcl	42	suppressed
Ondansetron Hcl	Ondansetron Hcl	39	25
Ropinirole Hcl	Ropinirole Hcl	39	suppressed
Levetiracetam	Levetiracetam	38	suppressed
Tramadol Hcl	Tramadol Hcl	38	13
Albuterol Sulfate Hfa	Albuterol Sulfate	37	15
Aripiprazole	Aripiprazole	36	suppressed
Cephalexin	Cephalexin	36	27
Pravastatin Sodium	Pravastatin Sodium	35	suppressed
Jardiance	Empagliflozin	34	suppressed
Spironolactone	Spironolactone	34	suppressed
Bumetanide	Bumetanide	33	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Mirabegron Er	Mirabegron	30	suppressed
Lamotrigine	Lamotrigine	29	suppressed
Tiotropium Bromide	Tiotropium Bromide	29	suppressed
Azithromycin	Azithromycin	28	11
Arexvy	Rsvpref3 Antigen/As01e/Pf	27	24
Trulicity	Dulaglutide	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Ondansetron Odt	Ondansetron	25	suppressed
Benztropine Mesylate	Benztropine Mesylate	24	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Ketoconazole	Ketoconazole	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Olanzapine	Olanzapine	23	suppressed
Dulera	Mometasone/Formoterol	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Meloxicam	Meloxicam	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Myrbetriq	Mirabegron	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	12
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Clonazepam	Clonazepam	19	suppressed
Sucralfate	Sucralfate	19	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Nystatin	Nystatin	16	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Ozempic	Semaglutide	16	suppressed
Allopurinol	Allopurinol	15	suppressed
Haloperidol Lactate	Haloperidol Lactate	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Pimecrolimus	Pimecrolimus	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Carbamazepine	Carbamazepine	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Atenolol	Atenolol	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Digoxin	Digoxin	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Vraylar	Cariprazine Hcl	12	suppressed
Amiloride Hcl	Amiloride Hcl	11	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Methenamine Hippurate	Methenamine Hippurate	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Oxcarbazepine	Oxcarbazepine	11	suppressed
Simvastatin	Simvastatin	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Zenpep	Lipase/Protease/Amylase	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error